Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Perdana NR, Mochtar CA, Umbas R, Hamid AR. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones 2016;48:228–38.
   PubMed Web of Science ®Google Scholar
• Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA 2017;317:2532–42.
   PubMed Web of Science ®Google Scholar
• Devlin HL, Mudryj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009;274:177–86.
   PubMed Web of Science ®Google Scholar
• Schroder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53:1129–37.
   PubMed Web of Science ®Google Scholar
• Ingrosso G, Detti B, Scartoni D, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol 2018;45:303–15.
   PubMed Web of Science ®Google Scholar
• Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 2011;29:3686–94.
   PubMed Web of Science ®Google Scholar
• Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579–85.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–65.
   PubMed Web of Science ®Google Scholar
• Tannock LF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–7.
   PubMed Web of Science ®Google Scholar
• Wu LH, Annie Bligh SW, Leon CJ, et al. Chemotaxonomically significant roburic acid from section cruciata of gentiana. Biochem Syst Ecol 2012;43:152–5.
   Web of Science ®Google Scholar
• Verhoff M, Seitz S, Paul M, et al. Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1. J Nat Prod 2014;77:1445–51.
   PubMed Web of Science ®Google Scholar
• Hou SB, Wang X, Huang R, et al. Seven new chemical constituents from the roots of Gentiana macrophylla pall. Fitoterapia 2020;141:104476.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ji N, Pan S, et al. Roburic acid suppresses NO and IL-6 production via targeting NF-κB and MAPK pathway in RAW264.7 cells. Inflammation 2017;40:1959–66.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Seyfried T, Alfarouk KO, et al. Out of Warburg effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH. Semin Cancer Biol 2017;43:134–8.
   PubMed Web of Science ®Google Scholar
• Pillai SR, Damaghi M, Marunaka Y, et al. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev 2019;38:205–22.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Pilot C, Marunaka Y, Fais S. Targeting acidity in cancer and diabetes. BBA Rev Cancer 2019;1871:273–80.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Fais S. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opin Ther Pat 2020;30:15–25.
   PubMed Web of Science ®Google Scholar
• De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010;127:207–19.
   PubMed Web of Science ®Google Scholar
• Logozzi M, Mizzoni D, Angelini DF, et al. Microenvironmental pH and exosome levels interplay in human cancer cell lines of different histotypes. Cancers 2018;10:370.
   PubMed Web of Science ®Google Scholar
• Wang BY, Zhang J, Wang JL, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015;34:85
   PubMed Web of Science ®Google Scholar
• Falcone R, Roberto M, D'Antonio C, et al. High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: a case series and the state of art. Dig Liver Dis 2016;48:1503–5.
   PubMedGoogle Scholar
• Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med 2013;11:268.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Baldi A, Buglioni S, et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Buglioni S, Carocci F, et al. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014;12:225.
   PubMed Web of Science ®Google Scholar
• Papagerakis S, Bellile E, Peterson LA, et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res 2014;7:1258–69.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lee CZ, Lin YC, et al. Negative association of proton pump inhibitors with subsequent development of breast cancer: a nationwide population-based study. J Clin Pharmacol 2019;59:350–5.
   PubMed Web of Science ®Google Scholar
• Ding DC, Sung FC, Chen W, et al. Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: a population-based cohort study. Breast J 2020;26:474–8.
   PubMed Web of Science ®Google Scholar
• Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80:925–37.
   PubMed Web of Science ®Google Scholar
• Ikemura K, Hiramatsu S, Okuda M. Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy. Front Pharmacol 2017;8:911.
   PubMed Web of Science ®Google Scholar
• Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 2015;356:697–703.
   PubMed Web of Science ®Google Scholar
• Huang H, Chen X, Li D, et al. Combination of α-tomatine and curcumin inhibits growth and induces apoptosis in human prostate cancer cells. PLOS One 2015;10:e0144293.
   PubMed Web of Science ®Google Scholar
• Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008;26:2862–70.
   PubMed Web of Science ®Google Scholar
• Pietras A. Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011;112:255–81.
   PubMed Web of Science ®Google Scholar
• Portillo-Lara R, Alvarez MM. Enrichment of the cancer stem phenotype in sphere cultures of prostate cancer cell lines occurs through activation of developmental pathways mediated by the transcriptional regulator ΔNp63α. PLOS One 2015;10:e0130118.
   PubMed Web of Science ®Google Scholar
• Gao W, Wu D, Wang Y, et al. Development of a novel and economical agar-based non-adherent three-dimensional culture method for enrichment of cancer stem-like cells. Stem Cell Res Ther 2018;9:243.
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med 2017;23:1124–34.
   PubMed Web of Science ®Google Scholar
• Fradet V, Lessard L, Begin LR, et al. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer . Clin Cancer Res 2004;10:8460–4.
   PubMed Web of Science ®Google Scholar
• Kim SM, Lee SY, Cho JS, et al. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol 2010;631:1–9.
   PubMed Web of Science ®Google Scholar
• Shaikh IA, Brown I, Schofield AC, et al. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 2008;68:1635–46.
   PubMed Web of Science ®Google Scholar
• Shrum CK, Defrancisco D, Meffert MK. Stimulated nuclear translocation of NF-kappaB and shuttling differentially depend on dynein and the dynactin complex. Proc Natl Acad Sci USA 2009;106:2647–52.
   PubMed Web of Science ®Google Scholar
• Chaudhary KS, Abel PD, Lalani EN. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 1999;107:49–57.
   PubMed Web of Science ®Google Scholar
• Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008;76:939–46.
   PubMed Web of Science ®Google Scholar
• Sabour R, Harras MF, Al Kamaly OM, Altwaijry N. Discovery of novel 3-cyanopyridines as surviving modulators and apoptosis inducers. Molecules 2020;25:4892.
   PubMed Web of Science ®Google Scholar